Novartis analyses confirm benefit of Kymriah® with clinically meaningful rates of complete response seen in patients with certain advanced lymphomas

  • Interim analysis from the investigational ELARA study shows, 65% of patients with r/r follicular lymphoma evaluated for efficacy achieved a complete response and the overall response rate was 83%1
  • Longer-term median follow-up of 40 months from the JULIET study showed a 33% two-year progression-free survival rate in patients with r/r DLBCL2
  • Both ELARA and JULIET trials reaffirm safety profile of Kymriah with no new short- or long-term safety signals identified

Basel, December 5, 2020 …

/by

Novartis announces first data from REACH3 trial showing Jakavi® (ruxolitinib) significantly improved outcomes in patients with steroid-resistant/dependent chronic GvHD

  • Results of REACH3 trial also demonstrate significant improvements in failure-free survival (FFS) and patient-reported symptoms1
  • Chronic graft-versus-host disease (GvHD) is a life-threatening complication of stem cell transplants and half of patients become steroid refractory/dependent2,3
  • Findings from the study were presented …
/by

The Co-Creating Impact Summit for the society and the planet

At Novartis, we know that our impact extends beyond the lives we touch with our medicines, and the performance we deliver for our stakeholders. We aim to have a positive impact on the communities in which we work, and build trust with society.

Our flagship Co-Creating Impact Summit on December 9, 2020, will provide an opportunity to build on the work we have already done in this area, and articulate the social, environmental and economic impact Novartis has on society, and on our planet.

With the rapidly changing ESG landscape, amplified by the COVID-19 pandemic, the upcoming …

/by

Why healthcare’s digital moment is now

In this fireside chat, Bertrand and Peter explore Microsoft’s health moonshots, COVID response and more.

/by

Why healthcare’s digital moment is now

In this fireside chat, Bertrand and Peter explore Microsoft’s health moonshots, COVID response and more.

/by

Novartis at ASH

Portrait picture of Nana, a sickle cell patient in Ghana

Novartis 2020 ASH Annual Meeting Virtual Portal

Novartis presence at ASH:

…

/by

Meet Novartis Management 2020

This annual event gives investors and industry analysts an opportunity to meet with Novartis executives who share deep insights into the company’s growth, pipeline and strategy.

We have delivered strong operational performance over the last three years and are positioned to maintain the momentum. The executives highlighted five assets that are growth drivers in major therapeutic areas, as well as five mid-to-late stage assets in Oncology and six mid-to-late stage assets in Pharmaceuticals with key milestones expected in 2021 and 2022.

We are also taking significant steps to …

/by

Novartis highlights confidence in growing sales with margin expansion, fueled by in-market brands and a rich pipeline, at Annual Meet the Management investor event

  • Novartis showcases unique profile with therapeutic area breadth and depth, exposure to cutting edge platforms and diversification of revenues in terms of assets and geographies
  • Key growth drivers now contributing to 48% of Innovative Medicines sales; upcoming launches expected to lay the foundation for future sales expansion
  • Advancing leading pipeline based on scale, …
/by

New hope for treating inflammatory diseases of the kidney

At age 14, Gisela Delgado felt unwell. She thought she had the flu, but when she noticed blood in her urine, she rushed to the emergency room.1

Six months later, in 1994, she was diagnosed with IgA nephropathy (IgAN), a kidney disease in which the body’s immune system attacks and slowly destroys the kidneys. There were no approved therapies for the disease. In the coming years, Delgado would lose weight and energy, and her quality of life would decline. Within 25 years, her doctors told her, her kidneys would probably fail. 

“It was my first year of high school. I …

/by

Novartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy

  • Novartis enters into exclusive worldwide license with Mesoblast to develop, commercialize and manufacture remestemcel-L for treatment of acute respiratory distress syndrome (ARDS) and other indications
  • Addition of remestemcel-L could expand Novartis respiratory portfolio by adding potential first-in-class ARDS therapy using innovative cell-based technology with platform potential
  • Deal includes $50 million upfront …
/by